11 To 14 Amino Acid Residues In Defined Sequence Patents (Class 530/327)
  • MODULATORS OF STAT3 SIGNALLING
    Publication number: 20110098218
    Abstract: The invention relates to methods for identifying compounds which modulate the interaction between STAT3 an SP1. A peptide is provided which is able to bind STAT3 and interfere with the interaction of STAT3 and SP1. The invention provides methods for identifying compounds which are capable of binding to the peptide and thus release interference with the interaction between STAT3 and SP1, as well as methods for identifying inhibitors and enhancers of the STAT3 SP1 interaction. Compounds identified by the methods of the invention are useful in the repression or stimulation of appetite in a patient, useful for the treatment of leptin resistance, obesity and anorexia.
    Type: Application
    Filed: June 1, 2009
    Publication date: April 28, 2011
    Applicant: Agency for Science, Technology and Research
    Inventors: Weiping Han, Guoqing Yang
  • NOVEL PEPTIDES DERIVED FROM NCAM (FGLs)
    Publication number: 20110098225
    Abstract: The present invention relates to novel compounds comprising at most 13 contiguous amino acid residues derived from the fibronectin type 3,I1 module of neural cell adhesion molecule (NCAM), or a variant or fragment thereof, capable of interacting with an FGFR and thereby the compounds are capable of inducing differentiation, modulating proliferation, stimulate regeneration, neuronal plasticity and/or survival of cells. Further, the present invention relates to the use of said compounds for production of a medicament for treatment of conditions and diseases, wherein NCAM and/or FGFR play a prominent role.
    Type: Application
    Filed: November 28, 2008
    Publication date: April 28, 2011
    Inventors: Vladimir Berezin, Elisabeth Bock, Søren Ebdrup, Boris Klementiev
  • PEPTIDES AND METHODS OF USE AS THERAPEUTICS AND SCREENING AGENTS
    Publication number: 20110098215
    Abstract: Host RNA/viral protein interaction as a target of intervention in the replication of viruses, e.g., the human immunodeficiency virus (HIV) are described. The target being upstream of the final replication product, and being crucial to the viral replication, is less likely to be genetically altered to drug resistance. Peptides that intervene in this RNA/viral protein interaction are also described, as well as compositions containing the same and methods of use thereof.
    Type: Application
    Filed: January 16, 2009
    Publication date: April 28, 2011
    Inventor: Paul F. Agris
  • Antifungal paints and coatings
    Patent number: 7932230
    Abstract: Antifungal and antibacterial peptides, polypeptides and proteins as antifungal additives for paint and other coatings are disclosed, along with antifungal compositions, and coated surfaces with antifungal properties. Methods of using the coatings for treating and/or inhibiting growth of mold, mildew and other fungi and bacteria on objects such as building materials that are susceptible to such infestation are also disclosed.
    Type: Grant
    Filed: August 18, 2009
    Date of Patent: April 26, 2011
    Assignee: Reactive Surfaces, Ltd., LLP
    Inventor: C. Steven McDaniel
  • Compositions and methods for the control of mammary cell number
    Patent number: 7932229
    Abstract: The present invention provides new methods and uses of peptides in effecting a reduction in mammary cell number. The discovery that these peptides reduce mammary cell number further enables the use of these peptides in the treatment of cancer where the peptides can be used to reduce cell number and accordingly reduce or prevent tumour development. The inventor has further shown that the peptides have specific utility in the treatment of breast cancer.
    Type: Grant
    Filed: October 21, 2005
    Date of Patent: April 26, 2011
    Assignee: AvantiCell Science Ltd
    Inventor: Colin James Wilde
  • Mass Spectrometry Quantitation of P450 Isoforms in Hepatocytes
    Publication number: 20110091981
    Abstract: A method for screening a drug for cytochrome P450 (CYP) induction is provided and can include incubating the drug with a microsome-containing biological sample and then quantitating at least one cytochrome P450 isoform. The isoforms can be selected from 2B6, 3A4, 1A2, and 3A5 isoforms. In some embodiments, the method uses liquid chromatography tandem mass spectrometry (LC-MSMS). A quantitated value can be compared to a threshold value and the drug can be determined to exhibit an acceptable CYP induction potential when the quantitated value does not exceed the threshold value. Isolated peptides are also provided.
    Type: Application
    Filed: October 14, 2010
    Publication date: April 21, 2011
    Applicant: DH TECHNOLOGIES DEVELOPMENT PTE. LTD.
    Inventors: Brian L. Williamson, Subhasish Purkayastha
  • POLYPEPTIDE AND PHARMACEUTICAL COMPOSITION CONTAINING THE POLYPEPTIDE
    Publication number: 20110092427
    Abstract: Disclosed is a novel polypeptide which can inhibit angiogenesis. Also disclosed is use of the polypeptide. The polypeptide comprises at least one amino acid sequence selected from the amino acid sequences depicted in SEQ ID NOs: 1-3, is composed of 120 or less amino acid residues, and has an anti-angiogenic activity. The polypeptide has an anti-angiogenic activity, has a lower molecular weight compared with that of PEDF, and has excellent penetration or absorption into a living body, particularly an affected part in a living body.
    Type: Application
    Filed: March 17, 2009
    Publication date: April 21, 2011
    Applicants: National University Corporation Hokkaido Universit y, Kurume University
    Inventors: Riichiro Abe, Hiroshi Shimizu, Kazuo Nakamura, Takanori Matsui, Tsutomu Imaizumi, Sho-ichi Yamagishi
  • Canine Anti-CD20 Antibodies
    Publication number: 20110091483
    Abstract: The invention provides canine CD20 specific antibodies, methods of making the antibodies and methods of use of the antibodies.
    Type: Application
    Filed: November 8, 2010
    Publication date: April 21, 2011
    Inventor: MELISSA J. BEALL
  • ANTI-IL 13 HUMAN ANTIBODIES
    Publication number: 20110091458
    Abstract: The present invention relates to human anti-IL-13 binding molecules, particularly antibodies, and to methods for using anti-IL-13 antibody molecules in diagnosis or treatment of IL-13 related disorders, such as asthma, atopic dermatitis, allergic rhinitis, fibrosis, inflammatory bowel disease and Hodgkin's lymphoma.
    Type: Application
    Filed: December 22, 2010
    Publication date: April 21, 2011
    Inventors: Emma CAMPBELL, Sofia Parveen, Joe Buechler, Gunars Valkirs
  • Peptide manufacturing process
    Publication number: 20110092671
    Abstract: A process for the manufacture of peptide Omiganan in solution phase. Novel intermediates in the process for the manufacture of Omiganan and processes for the manufacture of these intermediates.
    Type: Application
    Filed: June 17, 2008
    Publication date: April 21, 2011
    Applicant: SOLVAY (SOCIETE ANONYME)
    Inventors: Roland Callens, Laurent Jeannin, Georges Blondeel
  • Peptide Conjugate for Oral Delivery of Hydrophilic Peptide Analgesics
    Publication number: 20110092448
    Abstract: The present invention provides a method of improving the oral delivery of a parent peptide, comprising the step of linking the parent peptide to an added peptide to form a conjugate which has greater oral bioavailability than the parent molecule alone, the added peptide comprising a balance of hydrophobic and hydrophilic residues as defined herein. Conjugates for use in the method are also provided, as are pharmaceutical compositions comprising the conjugate and methods of treatment using the conjugate or pharmaceutical composition.
    Type: Application
    Filed: August 2, 2006
    Publication date: April 21, 2011
    Applicant: METABOLIC PHARMACEUTICALS LIMITED
    Inventor: Christopher Ian Belyea
  • COMPOSITIONS AND METHODS FOR MODULATING DOPAMINE NEUROTRANSMISSION
    Publication number: 20110091467
    Abstract: The present invention provides for diagnosis or treatment of neurological or neuropsychiatric disorders involving abnormal dopamine neurotransmission. Methods and agents are provided for modulating dopamine transporter activity and modulating dopaminergic neurotransmission. Agents of the present invention include fragments of D2 receptor or dopamine transporter (DAT) that can disrupt D2-DAT coupling.
    Type: Application
    Filed: October 14, 2010
    Publication date: April 21, 2011
    Inventor: FANG LIU
  • Chimeric Relaxin Polypeptides Comprising an A and B Chain Derived From Different Relaxin Family Peptides
    Publication number: 20110092418
    Abstract: Provided herein are modified relaxin polypeptides wherein the B chain comprises the core amino acid sequence CGR-XXX-R-XX-I/V-XX-CG (SEQ ID NO:1), where X is any amino acid. Also provided are modified relaxin polypeptides comprising at least an A and a B chain, wherein the A and B chains are derived from different naturally occurring relaxins and wherein the B chain comprises the core amino acid sequence CGR-XXX-R-XX-I/V-XX-CG (SEQ ID NO:1), where X is any amino acid.
    Type: Application
    Filed: October 30, 2008
    Publication date: April 21, 2011
    Applicant: FLOREKY INSTITUTE OF EXPERIMENTAL PHYSIOLOGY AND MEDICINE
    Inventors: Ross Alexander David Bathgate, Mohammed Akhter Hossain, Chrishan Surendran Samuel, John Desmond Wade, Geoffrey W. Tregear
  • Peptide for inhibition of calcineurin, nucleic acid, antibody, and diagnostic and therapeutic methods of use
    Patent number: 7928057
    Abstract: The present invention relates to a method for diagnosing susceptibility for a myocardial and/or immunological disorder, a kit and a therapeutic agent comprising a peptide of SEQ ID NO: 1 or 2 and uses thereof.
    Type: Grant
    Filed: January 25, 2007
    Date of Patent: April 19, 2011
    Assignee: Julius-Maximilians-Universitaet Wuerzburg
    Inventor: Oliver Ritter
  • Enzyme treatment of foodstuffs for Celiac Sprue
    Patent number: 7928056
    Abstract: Administering an effective dose of glutenase to a Celiac or dermatitis herpetiformis patient reduces levels of toxic gluten oligopeptides, thereby attenuating or eliminating the damaging effects of gluten.
    Type: Grant
    Filed: October 29, 2007
    Date of Patent: April 19, 2011
    Assignee: The Board of Trustees of the Leland Stanford Junior University
    Inventors: Felix Hausch, Gary Gray, Lu Shan, Chaitan Khosla
  • CONJUGATE OF A POLYMER, AN ANTI-ANGIOGENESIS AGENT AND A TARGETING MOIETY, AND USES THEREOF IN THE TREATMENT OF BONE RELATED ANGIOGENESIS CONDITIONS
    Publication number: 20110085979
    Abstract: Conjugates of hydroxypropyl methacrylamide (HPMA)-derived copolymers having attached thereto TNP-470 and a high load (e.g., higher than 3 mol %) of alendronate (ALN), and processes of preparing same are disclosed. Conjugates of polymers or copolymers having attached thereto an anti-angiogenesis agent and an oligoaspartate bone targeting agent, and processes of preparing same, are further disclosed. Pharmaceutical compositions containing these conjugates and uses thereof in the treatment and monitoring of bone related disorders are also disclosed.
    Type: Application
    Filed: May 21, 2009
    Publication date: April 14, 2011
    Applicants: Ramot at Tel-Aviv University Ltd., University of Utah Research Foundation
    Inventors: Ronit Satchi-Fainaro, Ehud Segal, Jindrich Kopecek, Pavla Kopeckova, Huaizhong Pan
  • ENHANCED ORAL TRANSCOMPARTMENTAL DELIVERY OF THERAPEUTIC OR DIAGNOSTIC AGENTS
    Publication number: 20110087004
    Abstract: The invention is directed to pharmaceutical compositions and methods for delivery of a therapeutic or diagnostic agent from one bodily compartment to one or more other bodily compartment by administering one of the following conjugates: a polymer having multiple functional groups at least one of which is covalently bound to a therapeutic or diagnostic agent, and at least one cell uptake promoter covalently bound to the therapeutic or diagnostic agent; or a polymer and at least one cell uptake promoter bound thereto; the polymer further comprising multiple functional groups at least one of which is covalently bound a therapeutic or diagnostic agent.
    Type: Application
    Filed: June 18, 2010
    Publication date: April 14, 2011
    Inventors: Srinivasan Ramanathan, Stanley Stein, Michael Leibowitz, Patrick J. Sinko, Tamara Minko, Gregory C. Williams, Goubao Zhang, Xiaoping Zhang, Shahrair Pooyan, Seong Hee Park, Bo Qiu, Pankaj Paranjpe
  • HLA-BINDING PEPTIDE, PRECURSOR THEREOF, AND DNA FRAGMENT AND RECOMBINANT VECTOR CODING FOR SAID HLA-BINDING PEPTIDE
    Publication number: 20110087005
    Abstract: An HLA-binding peptide binding to an HLA-A type molecule is provided that includes one or more types of amino acid sequence selected from the group consisting of SEQ ID NOS: 1 to 52, and not less than 8 and not more than 11 amino acid residues. All of these amino acid sequences are amino acid sequences predicted to bind to a human HLA-A molecule using a prediction program employing an active learning experiment method shown in FIG. 1.
    Type: Application
    Filed: November 16, 2010
    Publication date: April 14, 2011
    Applicants: NEC CORPORATION, KOCHI UNIVERSITY
    Inventors: Tomoya MIYAKAWA, Keiko UDAKA
  • HER2 PEPTIDES
    Publication number: 20110086055
    Abstract: Compositions, methods, and vaccines that may stimulate the immune system and that may be used for treating malignancies associated with overexpression of the HER-2 protein are provided. Such compositions include epitopes of the HER-2 proteins.
    Type: Application
    Filed: February 1, 2010
    Publication date: April 14, 2011
    Applicant: THE OHIO STATE UNIVERSITY RESEARCH FOUNDATION
    Inventor: Pravin Kaumaya
  • NOVEL ANTIMICROBIAL PEPTIDES
    Publication number: 20110085989
    Abstract: This invention provides novel antimicrobial peptides that are effective to inhibit growth and/or proliferation of various gram positive bacteria. In particular, the peptides are effective against Streptococcus mutans a common oral pathogen and the causative agent of dental caries.
    Type: Application
    Filed: March 24, 2010
    Publication date: April 14, 2011
    Inventors: Jian He, Randal H. Eckert, Fengxia Qi, Maxwell H. Anderson, Wenyuan Shi
  • Methods for diagnosing celiac sprue and reagents useful therein
    Patent number: 7923532
    Abstract: Administering an effective dose of glutenase to a Celiac or dermatitis herpetiformis patient reduces levels of toxic gluten oligopeptides, thereby attenuating or eliminating the damaging effects of gluten.
    Type: Grant
    Filed: October 29, 2007
    Date of Patent: April 12, 2011
    Assignee: The Board of Trustees of the Leland Stanford Junior University
    Inventors: Felix Hausch, Gary Gray, Lu Shan, Chaitan Khosla
  • SKIN WOUND HEALING COMPOSITIONS AND METHODS OF USE THEREOF
    Publication number: 20110082082
    Abstract: A wound healing composition comprising a class of polypeptide compounds having a polypeptide chain with 5 to 120 amino acid units per chain. The composition includes a pharmaceutical medium to carry the polypeptide compound, such as an aqueous solution, suspension, dispersion, salve, ointment, gel, cream, lotion, spray or paste. Additionally, a method of applying a wound healing composition comprising a class of polypeptide compounds having a polypeptide chain with 5 to 120 amino acid units per chain in a concentration of from about 1 pg/ml to about 100 ?g/ml for a time sufficient to heal the wound is disclosed.
    Type: Application
    Filed: July 17, 2009
    Publication date: April 7, 2011
    Applicant: UNIVERSITY OF SOUTHERN CALIFORNIA
    Inventors: Wei Li, Mei Chen, David T. Woodley, Chieh-Fang Cheng
  • ACTIVATING MUTATIONS OF PLATELET DERIVED GROWTH FACTOR RECEPTOR ALPHA (PDGFRA) AS DIAGNOSTIC MARKERS AND THERAPEUTIC TARGET
    Publication number: 20110081730
    Abstract: This disclosure provides tyrosine kinase protein and nucleic acid variants, particularly PDGFRA variants, which are activating forms of these molecules and are linked to neoplasms and/or the development or progression of cancer. The disclosure further provides methods of diagnosis and prognosis, and development of new therapeutic agents using these molecules and fragments thereof, and kits for employing these methods and compositions.
    Type: Application
    Filed: December 3, 2010
    Publication date: April 7, 2011
    Inventors: MICHAEL C. HEINRICH, CHRISTOPHER C. CORLESS, JONATHAN A. FLETCHER, GEORGE D. DEMETRI
  • BIOMARKERS FOR MONITORING OR PREDICTING THE TREATMENT OF CANCER
    Publication number: 20110082089
    Abstract: We provide for the diagnosis, prognosis and/or treatment monitoring of lung cancer or bronchial dysplasia, and the use thereof for predicting and monitoring therapeutic intervention in dysplasia or cancer patients. According to the invention at least one biomarker selected from the group consisting of APOE, APOC3, A1AT6, A2MG, PROP, TTHY, A1AG8, APOA1, APOH, GPX3, MUP8, RETBP, SAMP, VTDB, S6A11, EGFR, ApoA4, ApoM, a-raf, fetuin B, GSN, PLG, VPS28, and particular peptide sequences derived thereof, is used in the diagnosis, prognosis and/or treatment monitoring of cancer or dysplasia, in particular of lung cancer or the level of at least one of said biomarkers is measured in a body fluid sample, in particular in a blood serum sample, of a patient suffering from or being susceptible to cancer or dysplasia.
    Type: Application
    Filed: September 24, 2010
    Publication date: April 7, 2011
    Inventors: Jürgen Borlak, Bijon Chatterji
  • Imaging and therapeutic targeting of prostate and bladder tissues
    Patent number: 7919579
    Abstract: The present invention provides methods for imaging and the treatment of cancer. In certain embodiments, a polyarginine (e.g., R11) may be used to selectively image prostate or bladder cells (e.g., a metastatic prostate cancer). In other embodiments, a DOC-2/DAB2 peptide, optionally conjugated to a cell permeable peptide (e.g., R11) may be used to treat a cancer, such as prostate cancer.
    Type: Grant
    Filed: October 24, 2007
    Date of Patent: April 5, 2011
    Assignee: The Board of Regents of the University of Texas System
    Inventors: Jer-Tsong Hsieh, Jian Zhou, Xiankai Sun
  • Methods and compositions for altering mucus secretion
    Patent number: 7919469
    Abstract: Methods and compounds for increasing or decreasing mucus secretion in subjects, and particularly mucus secretion in the airways, are described. Methods of screening compounds for the ability to increase or decrease mucus secretion are also described.
    Type: Grant
    Filed: August 14, 2007
    Date of Patent: April 5, 2011
    Assignee: North Carolina State University
    Inventors: Yuehua Li, Linda D. Martin, Kenneth B. Adler
  • Polysaccharide-protein binding model and nano-fibril formation of a starch binding domain
    Patent number: 7919580
    Abstract: A polysaccharide-protein binding model of SBD, and a fibril-forming 14-residue peptide consisting of X1NNNX2X3NYQX4X5X6X7X8, wherein the X1 and X8 mean a pair of opposite charged amino acid residues, and the X2, X3, X4, X5, X6, or X7 means an amino acid residue is described. A mixture for diminising a polysaccharide, comprising at least two starch binding domains (SBDs) and a polysaccharide in a helix form is also presented. A method of providing an oligosaccharide, and a method of producing an amyloid-like fibril and use thereof are further described.
    Type: Grant
    Filed: January 23, 2009
    Date of Patent: April 5, 2011
    Assignee: National Tsing Hua University
    Inventors: Margaret Dah-Tsyr Chang, Yuh-Ju Sun, Ping-Chiang Lyu, Shu-Chuan Lin, Wei-I Chou
  • ANTIBODY-PEPTIDE FUSED SYNERGIBODY
    Publication number: 20110076723
    Abstract: Disclosed herein are synergibodies, antibody-peptide fused protein molecules containing antibodies and bioactive peptides, which function in the occurrence or progress of the identical disease.
    Type: Application
    Filed: May 22, 2009
    Publication date: March 31, 2011
    Applicant: SAMSUNG ELECTRONICS CO., LTD.
    Inventors: Brian Hosung Min, Jong Sang Ryu
  • PEPTIDES COMPRISING AN ISODGR MOTIF
    Publication number: 20110076234
    Abstract: Disclosed herein are peptides which include an isoDGR motif and which selectively inhibit ?v?3 integrin. In some embodiments, the isoDGR motif results from the deamidation of an NGR motif.
    Type: Application
    Filed: July 14, 2010
    Publication date: March 31, 2011
    Inventors: ANGELO CORTI, FLAVIO CURNIS
  • METHOD FOR DETECTION AND QUANTIFICATION OF PLK1 EXPRESSION AND ACTIVITY
    Publication number: 20110076693
    Abstract: Isolated peptide substrates of Plk1 and nucleic acids encoding these peptides are disclosed. The peptides include two to ten repeats of the amino acid sequence set forth as X1X2AX3X4X5PLHSTX6X7X8X9X10X11X12 (SEQ ID NO: 1), in which within each repeat X1, X2, X6, X7, X8, X9, X10, X11, and X12 are each independently any amino acid or no amino acid, and X3 and X4 are each independently any amino acid. Methods of using these peptides to detect Plk1 activity in a sample are also disclosed. In some examples, the method includes contacting a sample with a disclosed peptide substrate of Plk1 in the presence of adenosine triphosphate, or an analog thereof, for a period of time sufficient for Plk1 to phosphorylate the PBIPtide. The presence and/or amount of the phosphorylated and/or the unphosphorylated peptide is detected, thereby detecting and/or quantitating Plk1 kinase activity in the sample.
    Type: Application
    Filed: May 15, 2009
    Publication date: March 31, 2011
    Applicant: The U.S.A. as Represented by the Secretary , Dept.of Health and Human Services (the Gov.)
    Inventors: Kyung S. Lee, Jung Eun Park
  • Molecules Interfering with Binding of Calbindin to Inositol Monophosphatase for the Treatment of Mood Disorders
    Publication number: 20110076347
    Abstract: This invention provides derivatives of dodecapeptide ISSIKEKYPSHS which interfere with binding of calbindin to inositol monophosphatase, and their use in treating mood disorders.
    Type: Application
    Filed: May 14, 2009
    Publication date: March 31, 2011
    Inventors: Galila Agam, Orna Almog, Itzchak Levi, Yael Eskira, Yuly Bersudsky
  • NOVEL NPR-B AGONISTS
    Publication number: 20110077381
    Abstract: Disclosed are novel compounds having NPR-B agonistic activity. Preferred compounds are linear peptides containing 8-13 conventional or non-conventional L- or D-amino acid residues connected to one another via peptide bonds.
    Type: Application
    Filed: September 23, 2010
    Publication date: March 31, 2011
    Applicant: ALCON RESEARCH, LTD.
    Inventors: Frank Osterkamp, Heiko Hawlisch, Gerd Hummel, Tobias Knaute, Ulf Reimer, Ulrich Reineke, Uwe Richter, Bernadett Simon, Edgar Specker, Markus Woischnik, Mark R. Hellberg
  • Peptides for Inducing Heterosubtypic Influenza T Cell Responses
    Publication number: 20110076297
    Abstract: The present invention provides compositions and methods for generation of an anti-influenza immune response. In particular, conserved T cell epitopes within matrix protein and nucleoprotein components of influenza virus have been identified and further screened for those structures that will bind either or both of HLA I and II molecules. Methods for vaccinating subjects with formulations of such peptides for the treatment or prevention of influenza infaction also are described.
    Type: Application
    Filed: September 30, 2010
    Publication date: March 31, 2011
    Applicant: Saint Louis University
    Inventor: Daniel Hoft
  • Novel Antibacterial Peptides
    Publication number: 20110077192
    Abstract: The present invention relates to monomeric and multimeric peptidic compounds which have antimicrobial activity, particularly against Gram-positive and Gram-negative bacteria. Further, the present invention refers to compositions comprising said peptidic compounds for medical use, for use as a disinfectant and/or detergent or for use as a preservative.
    Type: Application
    Filed: June 2, 2009
    Publication date: March 31, 2011
    Applicant: SPIDERBIOTECH S.R.L.
    Inventors: Andrea Giuliani, Giovanna Pirri, Silvia Fabiole Nicoletto
  • IMMUNOGLOBULIN CLEAVAGE FRAGMENTS AS DISEASE INDICATORS AND COMPOSITIONS FOR DETECTING AND BINDING SUCH
    Publication number: 20110076264
    Abstract: The invention relates to antibody compositions and use of the composition to detect disease processes associated with elaboration of proteases. The reagents are directed to assessing an IgG breakdown product that is the result of such proteolytic cleavage. The invention further relates to the use of a therapeutic immunospecific for IgG protease cleavage products to restore effector function to antibody compositions that are subject to protease cleavage.
    Type: Application
    Filed: November 19, 2010
    Publication date: March 31, 2011
    Inventors: Robert Jordan, David Knight, Randall Brezski
  • Methods for isolation and analysis of sialylated and phosphorylated peptides
    Patent number: 7915008
    Abstract: Changes in sialylation of cell surface or plasma proteins are often associated with various cancers and other disease conditions. Provided are methods of detecting biomarkers of conditions associated with a change of sialylation status. Sialylated peptides are first isolated from biological and other samples by loading onto titanium dioxide (TiO2) or zirconium dioxide (ZrO2) stationary phase under acidic conditions in a solution comprising at least 20% organic phase and at least about 6.5 mM of substituted aromatic carboxylic acid, or, alternatively, at least about 11 mM short chain, non-aromatic, hydroxylated carboxylic acid. Sialic acid containing proteins can then be eluted from loaded stationary phase material by exposure to an alkaline solution having pH of 9.0 or greater, preferably at least 10.5.
    Type: Grant
    Filed: April 27, 2007
    Date of Patent: March 29, 2011
    Assignee: Syddansk Universitet
    Inventor: Martin Rossel Larsen
  • Antimicrobial agents
    Patent number: 7915223
    Abstract: A novel class of antimicrobial polymeric agents, which include a plurality of amino acid residues, such as positively charged amino acid residues, and at least one hydrophobic residue linking therebetween, such as an omega-amino-fatty acid residue, designed to exert antimicrobial activity while being stable, non-toxic and avoiding development of resistance thereto, and a process of preparing same, are disclosed. Further disclosed are pharmaceutical compositions containing same and a method of treating medical conditions associated with pathological microorganisms, a medical device, an imaging probe and a food preservative utilizing same. Further disclosed are conjugates of an amino acid residue and a hydrophobic moiety residue and a process of preparing same.
    Type: Grant
    Filed: August 8, 2006
    Date of Patent: March 29, 2011
    Assignee: Technion Research & Development Foundation Ltd.
    Inventors: Amram Mor, Inna Radzishevsky
  • IDENTIFICATION OF ANTIGENIC PEPTIDES FROM MULTIPLE MYELOMA CELLS
    Publication number: 20110070185
    Abstract: Multiple myeloma (MM) is a clonal B cell malignancy and remains essentially incurable by conventional anti-tumor therapy. Patients with MM have a median survival of only three years. MM is characterized by proliferation and accumulation of mature plasma cells in the bone marrow (BM) leading to bone destruction, BM failure, anemia, and reduced immune function. The identification of MHC Class I, HLA-A2, associated peptides presented on multiple myeloma cells is an important step in developing immunotherapies for MM. Presented here are methods for creating activated T lymphocytes that are cytotoxic to both peptide loaded T2 target cells and multiple myeloma cell lines.
    Type: Application
    Filed: September 22, 2009
    Publication date: March 24, 2011
    Inventors: Zeling Cai, Wei-Xing Shi, Xuejun P. Liu, Jiejun Wu
  • CANCER CELL MIGRATION AND CANCER CELL INVASION INHIBITOR
    Publication number: 20110070163
    Abstract: Provided are an antibody which binds specifically PAR1 (protease activated receptor 1) or a fragment of the antibody which retains similar characteristics thereto; a composition containing the same for inhibiting the migration activity and invasion activity of cancer cells; and a medicinal composition for treating cancer and the like.
    Type: Application
    Filed: March 19, 2009
    Publication date: March 24, 2011
    Applicant: TOHOKU UNIVERSITY
    Inventors: Kohsuke Gonda, Hideo Higuchi, Noriaki Ohuchi, Motohiro Takeda
  • Methods For Characterizing Antibody Binding Affinity And Epitope Diversity in Food Allergy
    Publication number: 20110071043
    Abstract: Methods for performing epitope mapping, and for characterizing the antibody binding affinity and epitope diversity of antibodies in a sample using peptide microarray are provided. In some aspects, methods are provided for the specific characterization of IgE and IgG4. Also disclosed are methods for diagnosing whether a milk-allergic individual will outgrow his or her allergy based on the characterization of the individual's milk allergen-specific IgE antibodies.
    Type: Application
    Filed: September 13, 2010
    Publication date: March 24, 2011
    Applicant: Mount Sinai School of Medicine of New York University
    Inventors: Hugh A. Sampson, Jing Lin, Ludmilla Bardina
  • TUMOUR-ASSOCIATED PEPTIDES BINDING TO MHC MOLECULES
    Publication number: 20110070253
    Abstract: The invention relates to a tumour-associated peptide with an amino acid sequence that is selected from the group consisting of SEQ ID NO: 1 to SEQ ID NO: 101 of the attached sequence protocol, wherein the peptide has the ability to bind to a molecule of the human major-histocompatibility-complex (MHC) class-I. In addition, the invention relates to the use of the peptides and the nucleic acids encoding for the peptides for the production of a medicament, and for the treatment of tumorous diseases and/or adenomatous diseases. Furthermore, a pharmaceutical composition is described that has at least one of the peptides.
    Type: Application
    Filed: October 29, 2010
    Publication date: March 24, 2011
    Applicant: IMMATICS BIOTECHNOLOGIES GMBH
    Inventors: Hans Georg RAMMENSEE, Stefan Stevanovic, Toni Weinschenk, Claudia Trautwein, Jörn Dengjel, Oliver Schoor
  • BIOACTIVE KERATIN PEPTIDES
    Publication number: 20110070276
    Abstract: Compositions containing biologically active peptides are disclosed. Active peptides are isolated fragments derived from human hair or sheep wool keratin proteins. Compositions may be prepared for pharmaceutical or topical administration or for use in cosmetic preparations.
    Type: Application
    Filed: February 26, 2009
    Publication date: March 24, 2011
    Inventor: Donald R. Cowsar
  • POLYPEPTIDES HAVING MODULATORY EFFECTS ON CELLS
    Publication number: 20110071087
    Abstract: The present invention relates to peptides and polypeptides having the sequence SAVTFAVCAL or variants thereof, capable of binding to Calcineurin and/or to NS5A-TP2 and to their use in therapy, as well as to nucleic acid sequences and vectors encoding these peptides and polypeptides, and to cells comprising said polypeptides, nucleic acid sequences or vectors. The invention further relates to the use of the peptides, polypeptides or their derivatives to bring about phenotypic changes in mammalian cells, particularly to up-regulate calcineurin activity. The invention finally relates to a method for intracellular identification of substances which bind to calcineurin and which modulate the physiological effects of calcineurin.
    Type: Application
    Filed: November 30, 2007
    Publication date: March 24, 2011
    Inventors: Pierre Colas, Benoit DeChassey, Ivan Jacques Mikaelian, Brian B. Rudkin
  • PEPTIDE COMPOSITION FOR CANCER TREATMENT BY INHIBITING TRPV6 CALCIUM CHANNEL ACTIVITY
    Publication number: 20110071089
    Abstract: The invention includes an isolated peptide comprising all or part of the amino acid sequence: EGKLSSNDTE GGLCKEFLHP SKVDLPR (SEQ ID NO: 1), wherein the peptide inhibits calcium channel activity. The peptides of the invention are useful for preventing or treating cancer.
    Type: Application
    Filed: September 20, 2010
    Publication date: March 24, 2011
    Applicant: SORICIMED BIOPHARMA INC.
    Inventor: John M. Stewart
  • Enzyme treatment of foodstuffs for celiac sprue
    Patent number: 7910541
    Abstract: Administering an effective dose of glutenase to a Celiac or dermatitis herpetiformis patient reduces levels of toxic gluten oligopeptides, thereby attenuating or eliminating the damaging effects of gluten.
    Type: Grant
    Filed: October 29, 2007
    Date of Patent: March 22, 2011
    Assignee: The Board of Trustees of the Leland Stanford Junior University
    Inventors: Felix Hausch, Gary Gray, Lu Shan, Chaitan Khosla
  • Conformationally constrained parthyroid hormone (PTH) analogs
    Patent number: 7910544
    Abstract: The invention provides novel P1R polypeptide antagonists. These antagonists contain amino acid substitutions at selected positions in truncated PTH and PRHrP polypeptides and function by binding selectively to the juxtamembrane (“J”) domain of the receptor. The J domain is the region of the receptor that spans the seven transmembrane domain and the extracellular loops.
    Type: Grant
    Filed: July 16, 2004
    Date of Patent: March 22, 2011
    Assignee: The General Hospital Corporation
    Inventors: Thomas J. Gardella, Naoto Shimizu, Henry M. Kronenberg, John T. Potts, Jr.
  • PROSTATE CANCER DIAGNOSIS AND TREATMENT
    Publication number: 20110064654
    Abstract: The present invention relates to novel antibodies and their use for detecting, imaging, staging, treating and monitoring of prostate cancer, and/or metastasis thereof. The present invention also relates to novel pharmaceutical compositions for the treatment of prostate cancer. Furthermore the present invention relates to assay systems and kits for detecting, imaging, staging, treating and monitoring of prostate cancer, and/or metastasis thereof.
    Type: Application
    Filed: September 10, 2010
    Publication date: March 17, 2011
    Applicant: Proscan Rx Pharma Inc.
    Inventors: Claudio Cuello, Uri Saragovi, Pierre Du Ruisseau, Phil Gold, Nicole Bernard, Serge Moffett
  • POLYETHER POLYOL DENDRON CONJUGATES WITH EFFECTOR MOLECULES FOR BIOLOGICAL TARGETING
    Publication number: 20110065896
    Abstract: Subject of the present invention are polyether polyol dendron conjugates comprising a specific polyether polyol dendron moiety, at least one certain fluorescent effector molecule (E). Such polyether polyol dendron conjugates may be used for diagnostic and therapeutic purposes, whereby the optical properties of the at least one certain fluorescent effector molecule are enhanced due to the attachment to the polyether polyol dendron conjugate.
    Type: Application
    Filed: March 10, 2009
    Publication date: March 17, 2011
    Applicant: MIVENION GMBH
    Inventors: Kai Licha, Malte Bahner, Michael Schirner, Rainer Haag, Timm Heek, Monika Wyszogrodzka
  • Method for the Identification of Extracellular Domains of Epstein Barr Virus (EBV) Tumor-Associated Latent Membrane Proteins and for the Selection of Antibody Reagents Reactive Therewith
    Publication number: 20110064759
    Abstract: Described are a method for the identification of extracellular epitopes of Epstein Barr virus (EBV) encoded membrane proteins, expressed on the cuter cell surface of EBV-transformed mammalian cells, methods for the selection and preparation of antibody reagents specific for the said epitopes, as well as peptides, including extracellular domains of Epstein Barr Virus encoded tumour cell associated membrane proteins, the use of said peptide for immunization and therapeutic vaccination to induce antibodies and T-cells reactive with said domains, the use of said antibody reagents for the production of targeting cells, tumour cell purging and as diagnostic for and medicament against EBV-mediated malignant cell growth.
    Type: Application
    Filed: August 17, 2010
    Publication date: March 17, 2011
    Applicant: CYTO-BARR B.V.
    Inventor: Jaap Michiel Middeldorp
  • ANTI-INVASIVE AND ANTI-ANGIOGENIC COMPOSITIONS
    Publication number: 20110065640
    Abstract: A peptide compound having the sequence Lys-Pro-Ser-Ser-Pro-Pro-Glu-Glu [SEQ ID NO:2] or a substitution variant, addition variant or other chemical derivative thereof inhibits cell invasion, endothelial tube formation or angiogenesis in vitro. A number of substitution variants and addition variants of this peptide, preferably capped at the N- and C-termini, as well as peptidomimetic derivates, are useful for treating diseases and conditions mediated by undesired and uncontrolled cell invasion and/or angiogenesis. Pharmaceutical compositions comprising the above peptides and derivatives are administered to subjects in need of such treatment in a dosage sufficient to inhibit invasion and/or angiogenesis. The disclosed compositions and methods are particularly useful for suppressing the growth and metastasis of tumors.
    Type: Application
    Filed: August 30, 2010
    Publication date: March 17, 2011
    Applicant: Angstrom Pharmaceuticals, Inc.
    Inventors: Andrew P. Mazar, Terence R. Jones